Business UpdateMay 13, 2026, 04:08 PM
Inovio Raises Going Concern Doubt; FDA Questions INO-3107 Accelerated Approval
AI Summary
Inovio Pharmaceuticals reported a net loss of $19.7 million for Q1 2026, with cash and equivalents decreasing to $26.3 million. The company disclosed substantial doubt about its ability to continue as a going concern beyond late Q4 2026, despite raising $16.0 million in an April 2026 offering. Additionally, the FDA accepted Inovio's BLA for INO-3107 for standard review but expressed preliminary concerns about its eligibility for the accelerated approval pathway, potentially requiring a costly Phase 3 trial.
Key Highlights
- Substantial doubt exists about Inovio's ability to continue as a going concern beyond late Q4 2026.
- FDA expressed preliminary concerns about INO-3107's eligibility for accelerated approval pathway.
- Net loss for Q1 2026 was $19.7 million, similar to $19.7 million in Q1 2025.
- Cash and cash equivalents decreased to $26.3 million as of March 31, 2026.
- Net proceeds of $16.0 million were raised from an April 2026 public offering.
- Total operating expenses decreased to $21.9 million in Q1 2026.
- Accumulated deficit reached $1.83 billion as of March 31, 2026.